Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
Stanford University
Stanford University
National Cancer Institute (NCI)
AstraZeneca
Genmab
Seagen Inc.
Mayo Clinic
STORM Therapeutics LTD
Neonc Technologies, Inc.
Ipsen
Bristol-Myers Squibb
Bayer
Pfizer
Radiopharm Theranostics, Ltd
Pfizer